



## Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call

March 20, 2024

MINNEAPOLIS, March 20, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2023 after the market closes on Wednesday, March 27, 2024. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.

### Webcast and Conference Call Information

To participate in the teleconference, domestic callers should dial 1-888-886-7786 or 1-416-764-8658. A live webcast presentation can also be accessed using this weblink:

[https://viaid.webcasts.com/starthere.jsp?ei=1655995&tp\\_key=04c7a07803](https://viaid.webcasts.com/starthere.jsp?ei=1655995&tp_key=04c7a07803). A replay of the webcast will be available on the Celcuity website following the live event.

### About Celcuity

Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are highly differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients. More detailed information about the VIKTORIA-1 study can be found at [ClinicalTrials.gov](https://clinicaltrials.gov). A Phase 1b/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is currently enrolling patients. The company's CELsignia companion diagnostic platform is uniquely able to analyze live patient tumor cells to identify new groups of cancer patients likely to benefit from already approved targeted therapies. Further information about Celcuity can be found at [Celcuity.com](https://celcuity.com). Follow us on [LinkedIn](#) and [Twitter](#).

### Contacts:

Celcuity Inc.

Brian Sullivan, [bsullivan@celcuity.com](mailto:bsullivan@celcuity.com)

Vicky Hahne, [vhahne@celcuity.com](mailto:vhahne@celcuity.com)

(763) 392-0123

ICR Westwicke

Maria Yonkoski, [maria.yonkoski@westwicke.com](mailto:maria.yonkoski@westwicke.com)

(203) 682-7167



News Provided by GlobeNewswire via QuoteMedia